Detail akcie XBiotech online

Business Summary: XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
Financial Summary: BRIEF: For the three months ended 31 March 2025, XBiotech Inc revenues was not reported. Net loss increased 9% to $10.9M. Higher net loss reflects Human Monoclonol Anti bodies segment loss increase of 25% to $13.6M, United States segment loss increase of 25% to $13.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.33 to -$0.36.